AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT03668340

Recruitment Status : Active, not recruiting

First Posted : September 12, 2018

Last Update Posted : January 3, 2024

View this study on the modernized ClinicalTrials.gov

Sponsor:

Collaborator:

AstraZeneca

Information provided by (Responsible Party):

Joyce Liu, MD, Dana-Farber Cancer Institute

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Active, not recruiting
Estimated Primary Completion Date :	December 31, 2024
Estimated Study Completion Date :	December 31, 2025

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Liu JF, Xiong N, Campos SM, Wright AA, Krasner C, Schumer S, Horowitz N, Veneris J, Tayob N, Morrissey S, West G, Quinn R, Matulonis UA, Konstantinopoulos PA. Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma. J Clin Oncol. 2021 May 10;39(14):1531-1539. doi: 10.1200/JCO.20.03167. Epub 2021 Mar 11.

To Top